mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga Technology 1/27/2026
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
View this post in the Community →
Similar Community Posts Join
1 / 1 resultscommunity Mallia Aesthetics achieves key regulatory steps for novel sCD83-derived ingredient for hair growth
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Related Research
5 / 5 results
research Telomere dysfunction impairs epidermal stem cell specification and differentiation by disrupting BMP/pSmad/P63 signaling
This study found that telomere shortening disrupts BMP/pSmad/P63 signaling, leading to skin atrophy via Follistatin up-regulation, and suggests potential therapeutic targets.
research Free androgen index (FAI)’s relations with oxidative stress and insulin resistance in polycystic ovary syndrome
This study found that in women with polycystic ovary syndrome, PCOS phenotype and oxidative stress markers were significantly related to free androgen index levels, but insulin resistance was not.
research The intragenic mRNA-microRNA regulatory network during telogen-anagen hair follicle transition in the cashmere goat
In this study, researchers found that microRNAs and specific target genes, such as MiR-195 and genes like CHP1, SMAD2, FZD6, and SIAH1, play significant roles in regulating hair follicle initiation in cashmere goats.
research Integration Analysis of Transcriptome and Proteome Reveal the Mechanisms of Goat Wool Bending
This study identified differentially expressed proteins and pathways potentially involved in wool bending in Zhongwei goats, with specific genes like COL6A1 and CRNN emerging as important candidates in this process.
research Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.